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A. INTRODUCTION
In this project, we conducted a clinical trial in which patients with multiple myeloma were treated with an anti-PD1 antibody (CT-011) alone (Cohort 1) and in conjunction with a dendritic cell/myeloma fusion cell vaccine (Cohort 2) following autologous transplantation. The goal of the project was to determine the effect of CT-011 alone, and in conjunction with a DC/myeloma fusion cell vaccine, to stimulate effective anti-tumor immunity and disease response.
B. BODY

Clinical Trial
The study is being conducted in two stages. In the first stage, a pilot study was conducted in which patients were treated with CT-011 alone following autologous transplant. The primary objective of this stage was to explore immunologic responses to CT-011 in the post-transplant period. The secondary objective was to assess the toxicity of treating patients with CT-011 in the post-transplant setting.
In the second stage, patients receive a combination of CT-011 and DC/myeloma fusion vaccination. The primary objective is to determine if cellular immunity is induced by treatment with monoclonal antibody CT-011 and DC/myeloma fusion cells in conjunction with stem cell transplant. The secondary objectives of this stage are: 1) To assess the toxicity associated with treating multiple myeloma patients with monoclonal antibody CT-O11 in combination with DC/myeloma fusion vaccine following autologous transplant, 2) To correlate levels of circulating activated and regulatory T cells with immunologic response, and 3) To define antitumor effects using serum markers, radiological studies, and time to disease progression. five patients did not meet eligibility criteria and three patients elected to pursue only standard of care therapy. To date, 62 participants have met eligibility criteria and have been enrolled: 27 patients on the first cohort (19 at DF/HCC and 8 at RMC) and 31 patients on the second cohort (28 at DF/HCC, 5 at RMC, and 2 at CHSH.)
A total of 19 participants have come off study prior to initiating study treatment, as summarized in Table 1 . Twelve participants were removed from Cohort 1 (10 at DF/HCC and 2 at RMC) and eight participants were removed from Cohort 2 (7 at DF/HCC and 1 at RMC.)
All participants enrolled onto the first cohort at both DF/HCC and RMC have completed treatment and active follow-up and are now in long-term follow-up.
Of the subjects enrolled onto the second cohort at DF/HCC, twelve have completed treatment and active follow-up, one has completed treatment and is now in active follow-up, five are currently receiving treatment, two have undergone both tumor collection and dendritic cell collection, and are completing induction chemotherapy, and one has undergone tumor collection but not dendritic cell collection, and is receiving induction chemotherapy Of the subjects enrolled onto the second cohort at RMC and CHSH, two are currently posttransplant and preparing for immunotherapy, three are currently receiving treatment, one has received transplant and is preparing to move forward with post-transplant immunotherapy, and one has undergone both tumor collection and dendritic cell collection, and is completing induction chemotherapy 
Subject Study Information
Treatment Related Serious Adverse Events:
There have been no treatment-related serious adverse events on Cohort 1.
Treatment Summary of Subjects that Died While on Study:
There have been two unrelated deaths on study, both on Cohort 1. The participants had not initiated study treatment. One participant died on 11/5/10 after suffering a cardiac arrest in his home; the event was reported to the Dana Farber Harvard Cancer Center IRB on 11/11/10.
Another participant committed suicide on 1/19/12; the event was reported to the Dana Farber
Harvard Cancer Center IRB on 1/20/12. Best response at the end of transplant was a very good partial response. Since completing treatment, the participant has remained in a very good partial response. Best response at the end of transplant was complete response. The participant developed progressive disease 24.5 months from transplant and was removed from the study. Best response at the end of transplant was a very good partial response. The participant developed progressive disease 18.9 months from transplant and was removed from the study. Best response at the end of transplant was a complete response. Since completing treatment, the participant has remained in a complete response. Best response at the end of transplant was a partial response. The participant experienced progressive disease 22 months from transplant and was removed from the study. Best response at the end of transplant was a very good partial response. Since completing treatment, the participant developed progressive disease 12.6 months from transplant and was removed from the study. Best response at the end of transplant was a very good partial response. Since completing treatment, the participant has remained in a very good partial response. Best response at the end of transplant was a partial response. The participant experienced progressive disease 6.6 months from transplant and was removed from the study. Best response at the end of transplant was a near complete response. Since completing treatment, the participant's response has transformed to a CR, 5 months from transplant during the second cycle of study treatment. He opted to start maintenance lenalidomide 16 months from transplant and was removed from study without progressing. Best response at the end of transplant was a very good partial response. The participant was removed from treatment due to an adverse event prior to receiving his third vaccine. Best response at the end of transplant was a near complete response. Since completing treatment, the participant's response has transformed to a CR, 1 month following his last infusion. 
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Treatment Related Serious Adverse Events:
There has been one serious adverse event related to study treatment on Cohort 2. On 10/11/13, participant PM35 presented to clinic for week 2 follow-up after his second infusion of CT-011 with grade 4 neutropenia (expected, probably related to CT-011 and vaccine.) The participant received neupogen per protocol. The participant returned again on 10/22/13, at which time his ANC had resolved to normal. The participant remained asymptotic and without infection. Per protocol, the participant was taken off treatment. This met the criteria for a DLT. This was reported to the FDA as S326 on 10/23/13. Unrelated AEs and SAEs are listed in the summary of unrelated adverse events in Table 7 . 
Potency of Fusion Cells as Antigen Present
C. REPORTABLE OUTCOMES
There are no updated reportable outcomes since last year.
D. KEY RESEARCH ACCOMPLISHMENTS
Based on the results of this research a phase II randomized trial of this cancer vaccine will be conducted through the oncology cooperative group sponsored by the National Heart Lung and Blood Institute at the NIH.
E. CONCLUSIONS
Autologous stem cell transplantation (ASCT) for multiple myeloma ( 
